Whether or not Stryker (SYK)
is the best-run med-tech company these days is a debatable subject, but
there's far less debate that the company's recent financial performance
has been exceptional. Couple that with industry valuations that are at
their highest level in a long, long time, and that is a powerful mix for
Stryker's share price performance.
Although I don't believe there was much, if any, substance to the rumors of Stryker approach Boston Scientific (BSX),
further M&A is a near-certainty, and Stryker has shown that it can
successfully integrate and build on the companies it buys. I am
concerned that there's not much room for sector valuation to go much
higher, but that's been a losing call for a while now and I wouldn't be
all that eager to short Stryker at this point.
Read more here:
Stryker Combining Industry-Leading Performance With Peaking Sector Valuations
No comments:
Post a Comment